| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
FY 2024 Guidance
The Group is introducing the below guidance for FY 2024 which reflects top line growth of 18% and adjusted operating margin expansion of approximately 300 basis points (at the midpoint) versus FY 2023.
Guidance assumes no material change in exchange rates for key currencies compared with FY 2023 average rates, notably USD/GBP and USD/EUR.
|
|
FY 2024 |
|
Net Revenue (NR)1 |
$1,240m to $1,330m (+18% at midpoint vs. FY 2023) |
|
SUBLOCADE NR |
$820m to $880m (+35% at midpoint vs. FY 2023) |
|
OPVEE® NR |
$15m to $25m1 |
|
PERSERIS NR |
$55m to $65m (+43% at midpoint vs. FY 2023) |
|
SUBOXONE Film Market Share |
Assumes historic rate of share decline in FY 2024 of 1 to 2 percentage points and the potential impact from a fourth buprenorphine/naloxone sublingual film generic in the U.S. market |
|
Adjusted Gross Margin |
Low to mid-80s range |
|
Adjusted SG&A |
($575m) to ($590m) |
|
R&D |
($120m) to ($130m) |
|
Adjusted Operating Profit |
$330m to $380m |
Posted In: INDV
